

## **Maiden AGM since IPO Commercialising world leading IP, driving revenues, expanding new market opportunities**

### **Highlights**

- Next Science's first AGM as a publically listed company
- Eliminating biofilms – building market awareness
- Superior healthcare solutions for wounds, infection treatment and prevention, acne and surface disinfection
- First pharma development – treatment for early stage skin cancers
- Expanding IP potential of XBIO into new market opportunities
- Focus on driving revenues – progress in expanding distribution networks

**Sydney, Australia, Wednesday, 25 September 2019:** Next Science Limited (ASX:NXS) (**Next Science** or **Company**) will today hold its first Annual General Meeting for shareholders since listing on ASX in April 2019.

Next Science is an established research and development company specialising in and commercialising biofilm solutions. Eighty percent of bacteria exist in biofilm structures posing a threat to human health and the environment. Next Science's XBIO technology is the only non-toxic solution that deconstructs biofilm, destroys bacteria and reduces the opportunity for biofilm to reform.

Since IPO, Next Science has made progress on executing on its two strategic priorities as outlined in the Prospectus:

1. Commence the growth of our revenue from the commercialisation of our IP this year.
2. Use the funds raised at IPO to accelerate the patented IP potential of XBIO across a broad suite of products and treatments to set the Company up for a long-term growth trajectory.

Ms. Judith Mitchell, Managing Director, noted, "We are pleased to host our maiden AGM as a public listed company. Since IPO, we have made encouraging progress in increasing the understanding of biofilms, expanding our market footprint and increasing the customer base.

In the next 12 months we have a number of important new product launches. These products should expand our opportunities into new markets and contribute to sales growth over time. These additional revenue streams will generate cash flow and strengthen our Company.

We are also excited to launch our first pharma development. Early indications suggest our treatment could offer an alternative solution in treating early stage skin cancers. We look forward to conducting the trial to establish this significant new market opportunity.

We approach 2020 with confidence and momentum. It should be a busy and productive year as we design and execute long-term growth strategies".

## Problems we are solving with regulated medical devices

DISEASE/ CONDITION	PRODUCT	MARKET LAUNCH	INDICATIONS	COMMERCIALISATION
Infected surgical field, or implanted prosthetic	<b>Bactisure</b> Surgical Lavage	April 2017	Removes biofilm and bacteria from any open surgery. Used to wash out a confirmed infection. Shown to be effective in treating Prosthetic Joint Infection (PJI)	Global distribution through Zimmer Biomet
Chronic and Acute Wounds	<b>BlastX</b> Antimicrobial Wound Gel	January 2018	Effective in the treatment of chronic wounds (Diabetic Foot Ulcers, Venous Leg Ulcers) and topical wounds.	Global distribution with 3M
Chronic and Acute Wounds	<b>TorrentX</b> Wound Wash	January 2019	Wound wash for all wounds/ non sterile environment	Distribution agreements in discussion, currently sold by Next Science
Chronic Sinusitis	<b>Sinus Wash out</b>	2H 2020	Chronic sinusitis being treated with FESS surgery or Sinus <u>Balloonplasty</u>	Global Distribution through Grace Medical. Regulatory submission moved to 1H 2020
Chronic Middle Ear Infection	<b>Middle Ear Wash</b>	2H 2020	Chronic middle ear infections being surgically treated with grommets and tubes	Global Distribution under discussion. Regulatory Submission 2H 2019

### Liquids and Gels as Treatments

## Problems we are preventing with regulated medical devices and disinfectants

DISEASE/ CONDITION	PRODUCT	MARKET LAUNCH	INDICATIONS	COMMERCIALISATION
Hospital Acquired Infection	<b>NS Disinfectant</b>	1H 2020	Removes biofilm from any hard surface. Shown to be effective against MRSA (Golden Staph) and Candida Auris	Distribution agreements under discussion. Waiting EPA approval
Surgical Site Infection	<b>SurqX Sterile Antimicrobial Wound Gel</b>	November 2018	Effective preventing the infection of the incision site	Sales currently through Next Science. Distribution moving to a 3 <sup>rd</sup> party distribution network in Q4 2019
Post Operative Surgical Infection	<b>Xbio Surgical Wash</b>	Mid 2020	Final wash for any surgical procedure (open or minimally invasive). Eliminates all bacteria, fungi and spores in the surgical field and is active for 5 hours post surgical close.	Broad distribution through a 3 <sup>rd</sup> party distribution network in the US and dedicated in country distribution specialists outside the US. Regulatory submission 2H 2019

### Liquids and Gels as Preventative Measures

- - - END - - -

### For further information, please contact:

Investors

**Michael Brown**

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

### About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary XBIO technology to reduce the impact of biofilm based infections in human health. XBIO is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO technology. For further information visit: [www.nextscience.com](http://www.nextscience.com).